Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 23.00p 20.00p 26.00p 23.00p 23.00p 23.00p 11,440 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.9 -7.8 -31.9 - 4.32

Genedrive PLC Trading update

17/01/2018 7:00am

UK Regulatory (RNS & others)

Genedrive (LSE:GDR)
Historical Stock Chart

1 Year : From Nov 2017 to Nov 2018

Click Here for more Genedrive Charts.


RNS Number : 0585C

Genedrive PLC

17 January 2018

For release: 17 January 2018

genedrive plc ("genedrive" or the "Company")

Trading Update

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, today provides an unaudited period end update for the six months ended 31 December 2017.

Group revenue was GBP2.6m (2016: GBP2.8m) with diagnostic (Genedrive(R)) related revenue of GBP1.3m (2016: GBP1.2m). Diagnostic revenue was largely comprised of the US Department of Defense project, with GBP1.0m of development income and GBP0.3m of product related sales.

genedrive has made significant strategic and operational progress in the period with the CE marking of its Genedrive(R) HCV ID Kit, the appointment of its distribution partner, Sysmex Corporation ("Sysmex"), in the EMEA and Asia Pacific regions, and the launch of the Hepatitis C test in Africa. Recently published field study results also demonstrated the robust performance of the HCV test in a third party setting and on territory specific samples. The Company continues to make good progress towards commercialising its Genedrive(R) HCV ID test and is performing in line with current expectations.

The Services division generated revenue of GBP1.3m (2016: GBP1.7m). While a disposal has yet to be secured in line with our strategic objective, discussions are ongoing and we remain optimistic that an appropriate divestment can be secured.

The Company closed the period with cash of GBP4.6m (30 June 2017: GBP5.1m), following the receipt of GBP1.2m R&D tax credits in the period.

David Budd, Chief Executive Officer of genedrive plc, said: "We are making good progress with the launch of the CE-marked Genedrive(R) HCV ID kit. This is an exciting period of growth and evolution for genedrive as we transition to a commercial stage point of care diagnostics company."

The Company expects to release results for the six months up to 31 December 2017 on 20 March 2018.

- Ends -

For further details please contact:

genedrive plc

David Budd: CEO +44 (0)161 989 0245

Matthew Fowler: CFO

Peel Hunt LLP

James Steel

+44 (0)207 418 8900

Oliver Jackson

Consilium Strategic Communications

Chris Gardner +44 (0)203 709 5700

Matthew Neal

Laura Thornton

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive(R) platform and MTB/RIF assay has been launched in India and a Genedrive(R) HCV test has received CE-IVD Certification and has been launched in Africa. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive(R) platform in the EMEA and Asia Pacific regions.

Further details can be found at: and

This information is provided by RNS

The company news service from the London Stock Exchange



(END) Dow Jones Newswires

January 17, 2018 02:00 ET (07:00 GMT)

1 Year Genedrive Chart

1 Year Genedrive Chart

1 Month Genedrive Chart

1 Month Genedrive Chart
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V:gb D:20181118 01:23:56